Myriad Genetics Inc. (MYGN) Tuesday reported third-quarter profit of $37.9 million or $0.46 per share, up from $29.6 million or $0.34 per share in same period last year.
On average, 17 analysts polled by Thomson Reuters expected the company to earn $0.40 per share for the quarter. Analysts' estimates typically exclude special items.
Revenues improved to $156.47 million from $129.78 million last year. Analysts expected revenues of $148.25 million.
Looking ahead, the company has raised its full-year 2013 earnings outlook to a range of $1.65 to $1.67 per share from the previous guidance of $1.55 to $1.58 per share.
Revenues are currently projected in a range of $595 million to $600 million, up from $575 million to $585 million, issued previously. Analysts currently expect the company to report full-year earnings of $1.58 per share on revenues of $583.50 million.
For comments and feedback: editorial@rttnews.com